Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG)
A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia
Sponsor: Amgen
Listed as NCT01624142, this PHASE2/PHASE3 trial focuses on Severe Familial Hypercholesterolemia and remains completed. Sponsored by Amgen, it has been updated 11 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Dec 2022 — Jun 2024 [monthly]
Completed PHASE2_PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2_PHASE3
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Jul 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2_PHASE3
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Amsterdam, Netherlands , Athens, Greece , Barcelona, Spain , Beirut, Lebanon , Brno, Czechia , Brussels, Belgium , Chicoutimi, Canada , Christchurch, New Zealand , Cincinnati, United States and 30 more locations